Statistics for Immunogenicity and safety following a homologous booster dose of a SARSCoV2 recombinant spike protein vaccine with MatrixMTM adjuvant NVXCoV2373 versus a primary series in people living with and without HIV1 infection in South Africa A randomized cro
Total visits
| views | |
|---|---|
| Immunogenicity and safety following a homologous booster dose of a SARSCoV2 recombinant spike protein vaccine with MatrixMTM adjuvant NVXCoV2373 versus a primary series in people living with and without HIV1 infection in South Africa A randomized cro | 1 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 1 |
| May 2025 | 0 |
File Visits
| views | |
|---|---|
| Journal Article.pdf | 5 |